Truist Securities Maintains Buy on Dianthus Therapeutics, Raises Price Target to $63
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $56 to $63.
Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $56 to $63.